Skip to content

Author

Passant E. Moustafa

We have 2 of 23 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Oct 2026

Saxagliptin Attenuates Thioacetamide-Induced Liver Fibrosis in Rats in Association with Changes in SIRT1/Nrf2/HO-1 Signaling, Oxidative Stress, and Apoptosis.

PURPOSE Currently, no universally effective treatment exists to stop or reverse the development of liver fibrosis. Saxagliptin (SAX), a dipeptidyl peptidase-4 (DPP-4) inhibitor, has demonstrated extra-glycemic benefits, including anti-inflammatory and anti-apoptotic properties, but its role in hepatic fibrogenesis has...

M. Alsugoor, N. Alsuhaymi, S. El Awdan et al. · 0 citations
Open access Jan 2026

Protective Role of Linagliptin in Cisplatin‐Mediated Liver Injury: Involvement of STAT3 and AMPK/SIRT1/PGC‐1alpha Mitochondrial Energy Sensing Networks

The results indicate that Lina protects against Cis‐induced liver damage by leveraging its antioxidant, anti‐inflammatory, and metabolic regulation properties.

M. A. Elbaset, Bassim M S A Mohamed, Passant E. Moustafa et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.